Literature DB >> 18282632

The use of Minilabs to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience.

Peter Gasper Risha1, Zera Msuya, Malcolm Clark, Keith Johnson, Margareth Ndomondo-Sigonda, Thomas Layloff.   

Abstract

The Tanzania Food and Drugs Authority piloted the use of Minilab kits, a thin-layer-chromatographic based drug quality testing technique, in a two-tier quality assurance program. The program is intended to improve testing capacity with timely screening of the quality of medicines as they enter the market. After 1 week training of inspectors on Minilab screening techniques, they were stationed at key Ports-of-Entry (POE) to screen the quality of imported medicines. In addition, three non-Ports-of-Entry centres were established to screen samples collected during Post-Marketing-Surveillance. Standard operating procedures (SOPs) were developed to structure and standardize the implementation process. Over 1200 samples were tested using the Minilab outside the central quality control laboratory (QCL), almost doubling the previous testing capacity. The program contributed to increased regulatory reach and visibility of the Authority throughout the country, serving as a deterrent against entry of substandard medicines into market. The use of Minilab for quality screening was inexpensive and provided a high sample throughput. However, it suffers from the limitation that it can reliably detect only grossly substandard or wrong drug samples and therefore, it should not be used as an independent testing resource but in conjunction with a full-service quality control laboratory capable of auditing reported substandard results.

Entities:  

Mesh:

Year:  2008        PMID: 18282632     DOI: 10.1016/j.healthpol.2007.12.010

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  18 in total

1.  Pill characterization data streams for reducing exposure to inadequately identified anti-malarial medication in developing countries.

Authors:  Peter Pennefather; Aria Ilyad Ahmad; Ian Crandall; West Suhanic
Journal:  Malar J       Date:  2010-07-22       Impact factor: 2.979

Review 2.  Substandard/counterfeit antimicrobial drugs.

Authors:  Theodoros Kelesidis; Matthew E Falagas
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

3.  Assessment of the quality of anti-tuberculosis medicines in Almaty, Kazakhstan, 2014.

Authors:  D Nabirova; G Schmid; R Yusupova; M Kantarbayeva; S I Ismailov; D Moffett; R W O Jähnke; J P Nuorti
Journal:  Int J Tuberc Lung Dis       Date:  2017-10-01       Impact factor: 2.373

4.  Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countries.

Authors:  Facundo M Fernandez; Dana Hostetler; Kristen Powell; Harparkash Kaur; Michael D Green; Dallas C Mildenhall; Paul N Newton
Journal:  Analyst       Date:  2010-11-25       Impact factor: 4.616

5.  Paper analytical devices for fast field screening of beta lactam antibiotics and antituberculosis pharmaceuticals.

Authors:  Abigail A Weaver; Hannah Reiser; Toni Barstis; Michael Benvenuti; Debarati Ghosh; Michael Hunckler; Brittney Joy; Leah Koenig; Kellie Raddell; Marya Lieberman
Journal:  Anal Chem       Date:  2013-06-18       Impact factor: 6.986

6.  Assessing the quality of anti-malarial drugs from Gabonese pharmacies using the MiniLab®: a field study.

Authors:  Benjamin J Visser; Janneke Meerveld-Gerrits; Daniëlle Kroon; Judith Mougoula; Rieke Vingerling; Emmanuel Bache; Jimmy Boersma; Michèle van Vugt; Selidji T Agnandji; Harparkash Kaur; Martin P Grobusch
Journal:  Malar J       Date:  2015-07-15       Impact factor: 2.979

7.  Quality of the antibiotics--amoxicillin and co-trimoxazole from Ghana, Nigeria, and the United Kingdom.

Authors:  Ifeyinwa Fadeyi; Mirza Lalani; Naiela Mailk; Albert Van Wyk; Harparkash Kaur
Journal:  Am J Trop Med Hyg       Date:  2015-04-20       Impact factor: 2.345

8.  Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.

Authors:  Albert Petersen; Nadja Held; Lutz Heide
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

Review 9.  Substandard drugs: a potential crisis for public health.

Authors:  Atholl Johnston; David W Holt
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 10.  Strategies and Systems-Level Interventions to Combat or Prevent Drug Counterfeiting: A Systematic Review of Evidence Beyond Effectiveness.

Authors:  Racha Fadlallah; Fadi El-Jardali; Farah Annan; Hayat Azzam; Elie A Akl
Journal:  Pharmaceut Med       Date:  2016-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.